CAMBRIDGE, Mass., September 21, 2021--(BUSINESS WIRE)--Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the appointment of Ian Sanderson, MBA, as Chief Financial Officer. He succeeds Holly Whittemore, CPA, who will transition to the newly created role of Chief Accounting Officer, reporting to Mr. Sanderson.
"Ian brings to Nimbus a wealth of experience in financial management, capital markets and strategic transactions, and we are excited to strengthen our leadership team by bringing him on board. We’re also very pleased that Holly will continue Nimbus’ financial operations in her new role. She has been an integral part of our success over the past 12 years, including serving as the architect of our innovative LLC business model," said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus. "These changes help position Nimbus for long-term growth to support our maturing pipeline and key milestones ahead."
Mr. Sanderson joins Nimbus from Boston Pharmaceuticals, where he served as Chief Financial Officer. He previously served as Chief Financial Officer at Catabasis Pharmaceuticals, where he led the company’s re-positioning initiative and successful IPO. Before joining the biopharma industry, Mr. Sanderson held a number of leadership roles in investment banking, including 20 years with Cowen and Company, where he was a senior equity research analyst covering the pharmaceuticals and specialty pharmaceuticals sectors. Mr. Sanderson holds an MBA in finance from the Wharton School of the University of Pennsylvania and a B.A. in political economy from Williams College.
"Nimbus has established a highly successful track record of discovering and developing innovative new therapeutics. Now, with multiple clinical trials on the near horizon, the company has even greater potential to transform patients’ lives," said Mr. Sanderson. "I look forward to working with Jeb and the talented team to leverage the Nimbus discovery platform to develop truly breakthrough medicines for patients."
About Nimbus Therapeutics
Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005247/en/
Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications